Borrelia antigen

Abstract

Disclosed and claimed are substantially pure OspA, vaccines including substantially pure OspA and an immunologically acceptable carrier or vehicle, methods for producing such vaccines, and methods for inducing a protective immunological response against Borrelia burgdorferi employing such vaccines. The methods for producing the vaccines can include admixing the OspA and the carrier or vehicle. The methods for producing the vaccines also can include recovering the OspA from a host organism transformed with a vector containing DNA encoding the OspA and admixing the OspA with an immunologically acceptable carrier or vehicle. Such methods can further include adding an adjuvant. The vaccine can contain OspA from two or more strains of Borrelia burgdorferi.

Dependencies are inferred from the claim text.